CK Regeon


CK Regeon Inc. founded by prof. Choi Kang-yeol, biotechnology at Yonsei University, in October 2016. CK Regeon Inc. develops First-in-Class drugs targeting CXXC5, a negative feedback regulator of the Wnt/beta-catenin pathway. CK Regeon secured pipelines for diabetic foot ulcers, obesity, diabetes, NASH, and regenerative treatment for hair loss.